A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Oral E7080 in Addition to Best Supportive Care (BSC) versus BSC Alone in Patients with Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Who Have Failed at Least Two Systemic Anticancer Regimens
Phase of Trial: Phase II
Latest Information Update: 28 Sep 2017
At a glance
- Drugs Lenvatinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Eisai Inc
- 28 Aug 2017 Status changed from active, no longer recruiting to completed.
- 24 Feb 2015 According to an Eisai Co media release, results were presented at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO) in 2014.
- 24 Feb 2015 Results published in an Eisai Co media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History